Open House - Global Healthcare 2022: Oxford Biomedica | Edison Group
Oxford Biomedica is a pioneer of gene and cell therapy with a leading position in lentiviral vector research and bioprocessing. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
-
John Dawson,, Chief Executive Officer, Oxford Biomedica
John Dawson joined Oxford Biomedica’s Board as a Non-Executive Director in August 2008, and was appointed Chief Executive Officer in October 2008. Prior to this he held senior management positions in the European operations of Cephalon Inc., including Chief Financial Officer and Head of Business Development Europe. While at Cephalon he led many deals building the European business to over 1,000 people and to a turnover of several hundred million US dollars. In 2005, Mr. Dawson led the $360 million acquisition of Zeneus by Cephalon. Prior to his time at Cephalon he was Director of Finance and Administration of Serono Laboratories (UK) Limited.
